Genfit (GNFTF) Stock Price, News & Analysis

Company Overview

Genfit S.A. is a biopharmaceutical company headquartered in Lille, France, focused on developing treatments for serious diseases with significant unmet medical needs. The company’s research has historically centered on liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), and has expanded to rare and life-threatening conditions affecting the liver and other organs.

Genfit’s portfolio includes therapies and investigational programs targeting acute-on-chronic liver failure, cholestatic liver diseases, and lysosomal acid lipase deficiency. Its most prominent product is elafibranor, marketed as Iqirvo. The therapy was developed by Genfit and is commercialized through a licensing and collaboration arrangement with Ipsen for the treatment of primary biliary cholangitis in certain patients.

Founded in 1999, Genfit serves international markets through research, development and commercial partnerships, with activities spanning Europe, North America and other regions. The company continues to advance a pipeline of drug candidates and diagnostic technologies designed to address complex liver and metabolic disorders. Genfit is led by Chief Executive Officer Pascal Prigent.

Key Stats

• Today's Range: $9.43 to $9.43
• 50-Day Range: $9.43 to $15.75
• 52-Week Range: $4.14 to $16.50
• Volume: 3 shs
• Average Volume: 600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genfit Stock Analysis - MarketRank™

Genfit scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genfit.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genfit is -14.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genfit is -14.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genfit has a short interest ratio ("days to cover") of 678.52, which indicates bearish sentiment.

Change versus previous month

Short interest in Genfit has recently increased by 64.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genfit does not currently pay a dividend.

Dividend Growth

Genfit does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Genfit has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genfit insiders have not sold or bought any company stock.

Percentage Held by Institutions

11.11% of the stock of Genfit is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:GNFTF
• CIK: N/A
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 192
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A